Stevanato Group S.p.A. Stock

Equities

STVN

IT0005452658

Medical Equipment, Supplies & Distribution

Market Closed - Nyse 16:00:02 2024-04-26 EDT 5-day change 1st Jan Change
27.54 USD +0.07% Intraday chart for Stevanato Group S.p.A. +3.03% +0.92%

Financials

Sales 2024 * 1.19B 1.28B 1.75B Sales 2025 * 1.34B 1.44B 1.96B Capitalization 7.06B 7.55B 10.32B
Net income 2024 * 161M 172M 235M Net income 2025 * 195M 208M 285M EV / Sales 2024 * 6.2 x
Net Debt 2024 * 351M 376M 514M Net Debt 2025 * 231M 247M 337M EV / Sales 2025 * 5.43 x
P/E ratio 2024 *
42.4 x
P/E ratio 2025 *
35.5 x
Employees 5,635
Yield 2024 *
0.25%
Yield 2025 *
0.28%
Free-Float 15.1%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.07%
1 week+3.03%
Current month-14.21%
1 month-13.37%
3 months-13.18%
6 months-4.94%
Current year+0.92%
More quotes
1 week
26.47
Extreme 26.4708
28.17
1 month
26.47
Extreme 26.4708
32.98
Current year
25.13
Extreme 25.13
34.73
1 year
23.00
Extreme 23
36.30
3 years
13.36
Extreme 13.355
36.30
5 years
13.36
Extreme 13.355
36.30
10 years
13.36
Extreme 13.355
36.30
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 17-12-31
Director of Finance/CFO 52 19-12-31
Chairman 51 09-12-31
Members of the board TitleAgeSince
Director/Board Member 78 12-12-31
Director/Board Member 64 21-04-30
Director/Board Member 67 18-08-31
More insiders
Date Price Change Volume
24-04-26 27.54 +0.07% 335,568
24-04-25 27.52 +0.77% 588,865
24-04-24 27.31 +0.33% 190,354
24-04-23 27.22 +2.56% 233,114
24-04-22 26.54 -0.71% 277,071

Delayed Quote Nyse, April 26, 2024 at 04:00 pm

More quotes
Stevanato Group SpA is an Italy-based manufacturer and distributor engaged in two segments: Biopharmaceutical and Diagnostic Solutions and Engineering, including the production and distribution of drug containment solutions, drug delivery systems, and diagnostic solutions in the pharmaceutical industry. The Company delivers products, processes, and services across all stages of drug developments, including pre-clinical, clinical, and commercialization. Its Engineering segment includes the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology, and diagnostic manufacturing processes. The Company operates locally, in Europe, and globally, including Brazil, China, Mexico, and the United States.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
27.54 USD
Average target price
35 USD
Spread / Average Target
+27.08%
Consensus